

Reference number(s)
2140-A

# SPECIALTY GUIDELINE MANAGEMENT

## RIBAVIRIN PRODUCTS (REBETOL, ribavirin capsules and tablets)

### POLICY

#### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

##### FDA-Approved Indications

##### Rebetol

Rebetol is indicated in combination with interferon alfa-2b (pegylated and nonpegylated) for the treatment of chronic hepatitis C (CHC) in patients 3 years of age and older with compensated liver disease.<sup>3</sup>

All other indications are considered experimental/investigational and not medically necessary.

#### II. EXCLUSIONS

Exclusions to other antiviral drugs being used in combination with the requested drug apply. Refer to the SGM policy for each drug in the treatment regimen for applicable exclusions.

#### III. CRITERIA FOR APPROVAL

##### **Hepatitis C virus (HCV) infection**

Refer to the SGM of requested regimen for the specific criteria for approval and approval durations.

#### IV. OTHER

Some elements outlined in this policy may not be enforced for certain plans due to regulatory guidelines.

#### V. REFERENCES

1. Rebetol [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; March 2022.
2. AASLD/IDSA/IAS–USA. Recommendations for testing, managing, and treating hepatitis C. <https://www.hcvguidelines.org>. Last changes made on October 5, 2021. Accessed August 9, 2022.
3. Sovaldi [package insert]. Foster City, CA: Gilead Sciences, Inc.; March 2020.
4. Viekira Pak [package insert]. North Chicago, IL: AbbVie Inc.; December 2019.
5. Zepatier [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; May 2022.
6. Epclusa [package insert]. Foster City, CA: Gilead Sciences, Inc.; April 2022.
7. Vosevi [package insert]. Foster City, CA: Gilead Sciences, Inc.; November 2019.
8. Mavyret [package insert]. North Chicago, IL: AbbVie Inc.; September 2021.
9. Harvoni [package insert]. Foster City, CA: Gilead Sciences; March 2020.